Education
About Us
Working with TipRanks
Follow Us
2cureX AB (DE:2QE)
:2QE
2QE Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.40
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€7.86M
Enterprise ValueN/A
Total Cash (Recent Filing)€3.13M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding17,602,917
10 Day Avg. Volume0
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
2QE FAQ
What was 2cureX AB’s price range in the past 12 months?
2cureX AB lowest stock price was €0.02 and its highest was €0.40 in the past 12 months.
What is 2cureX AB’s market cap?
2cureX AB’s market cap is €7.86M.
When is 2cureX AB’s upcoming earnings report date?
2cureX AB’s upcoming earnings report date is May 29, 2025 which is 9 days ago.
How were 2cureX AB’s earnings last quarter?
2cureX AB released its earnings results on May 29, 2025. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.012.
Is 2cureX AB overvalued?
According to Wall Street analysts 2cureX AB’s price is currently Overvalued.
Does 2cureX AB pay dividends?
2cureX AB does not currently pay dividends.
What is 2cureX AB’s EPS estimate?
2cureX AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 2cureX AB have?
2cureX AB has 17,602,917 shares outstanding.
What happened to 2cureX AB’s price movement after its last earnings report?
2cureX AB reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of 2cureX AB?
Currently, no hedge funds are holding shares in DE:2QE
Company Description
2cureX AB
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
Technical Analysis
Diagonal Bio AB
―
LIDDS AB
―
Scandion Oncology A/S
―
Lipigon Pharmaceuticals AB
―
QuiaPEG Pharmaceuticals Holding AB
―